News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • H World announced proposed CNY-denominated bond offering to non-U.S. persons under Regulation S.
  • H World said terms will be set at pricing and the offering requires regulatory approvals.
  • DSS launched proposed public offering of common stock to raise general corporate and working capital.
  • Aegis Capital is sole book-running manager for DSS's offering and the deal is subject to market conditions.
  • DSS's equity offering will increase share supply and may dilute existing shareholders.
  • Combined new debt and equity issuance increases market supply and may weigh on bond and equity prices.

Latest Articles

NOMAD Power Solutions, Inc. Receives DOE Authorization to Advance Vermont Long-Duration Energy Storage Project into Phase 3

NOMAD Power Solutions, Inc. Receives DOE Authorization to Advance Vermont Long-Duration Energy Storage Project into Phase 3

NOMAD Power Solutions, Inc. announced that it has received authorization from the U.S. Department of Energy to advance into Phase 3 of the Vermont Long Duration Energy Storage Demonstration Project. This $19 million project will deploy up to eight transportable battery energy storage units across five sites in Green Mountain Power's service territo…

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

Celcuity Inc. has submitted a supplemental New Drug Application to the FDA seeking approval of REVTORPYK (gedatolisib) for treatment of hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer patients with PIK3CA mutations. This follows positive Phase 3 VIKTORIA-1 trial results demonstrating significant progression-fre…

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

Autonomix Medical, Inc. announced the issuance of a new U.S. patent (No. 12,714,780) expanding its intellectual property portfolio around systems integrating real-time physiological feedback, sensing, and imaging with controlled therapeutic delivery. The patent covers precision nerve-targeted treatments including neural ablation for cancer pain rel…

Buy CLOV: AI-First Medicare Advantage at a Reasonable Growth Multiple

Buy CLOV: AI-First Medicare Advantage at a Reasonable Growth Multiple

Clover Health is an actionable long thanks to accelerating Medicare Advantage membership, demonstrable AI-driven care improvements, improving free cash flow and a valuation that prices growth modestly. This trade idea lays out a mid-term plan centered on enrollment catalysts and recurring care-management economics while flagging regulatory, data an…

ParaZero Reports Strong First Half 2026 Results with 195% Sales Growth and Expanding DefendAir Commercial Momentum

ParaZero Reports Strong First Half 2026 Results with 195% Sales Growth and Expanding DefendAir Commercial Momentum

ParaZero Technologies Ltd. announced a robust financial performance for the first half of 2026, with sales nearly tripling year-over-year to $1.06 million, surpassing the full-year 2025 sales. Gross margin improved dramatically from negative to positive 36%, driven by growth in defense-sector products and OEM integrations. The company secured multi…

PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio

PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio

PMGC Holdings Inc. has terminated its previously announced letter of intent to acquire a 76% stake in a precision machining company after financial due diligence revealed less favorable financials than initially expected. The company reaffirms its disciplined M&A approach and continues investing in its aerospace and defense manufacturing portfolio,…

Borealis Foods’ U.S. School Foodservice Revenue Grows 110% Year Over Year Amid National Expansion

Borealis Foods’ U.S. School Foodservice Revenue Grows 110% Year Over Year Amid National Expansion

Borealis Foods Inc. reported a 110% year-over-year revenue increase in the U.S. K–12 foodservice channel, fueled by expansion to over 20,000 schools and a rapidly growing distributor network spanning 40 states. The company’s versatile, nutritious food products are meeting strong demand from school nutrition programs, supporting operational efficien…

Candel Therapeutics to Present at September Investor Conferences

Candel Therapeutics to Present at September Investor Conferences

Candel Therapeutics, a clinical-stage biopharmaceutical company specializing in multimodal immunotherapies for cancer, announced that its CEO will participate in several prominent investor conferences in September 2026. The company highlighted its two clinical-stage immunotherapy platforms and ongoing clinical trials, along with regulatory designat…

StepStone Group Closes its Infrastructure Secondaries Fund, Raising $1.7 Billion Across the Fund and Related Separate Accounts

StepStone Group Closes its Infrastructure Secondaries Fund, Raising $1.7 Billion Across the Fund and Related Separate Accounts

StepStone Group Inc. announced the successful closing of its StepStone Secondaries Infrastructure Fund (SSIF) and related separate accounts with $1.7 billion in total capital commitments, surpassing its initial targets. This fund is dedicated to acquiring LP interests and investing in GP-led secondary infrastructure funds, leveraging StepStone's st…

PowerCompute GPU Deployment Achieves Verified Status on Vast.ai Marketplace; Company Adds Second Unit in Oklahoma

PowerCompute GPU Deployment Achieves Verified Status on Vast.ai Marketplace; Company Adds Second Unit in Oklahoma

PowerCompute announced their GPU deployed at the Oklahoma facility achieved Verified status on Vast.ai's compute marketplace, indicating top machine reliability and performance. The company plans to add a second GPU soon and aims for Certified Datacenter status by meeting ISO/IEC 27001 certification and deploying at least five GPUs. This expansion …

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

Odyssey Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, announced that its management team will participate in several investor conferences in September 2026, including Cantor Global Healthcare, Morgan Stanley Global Healthcare, and H.C. Wainwright Global Investment Conferences. The company …

CTS Corporation Expands Availability of Current Sensing Solutions Through Authorized Distribution Partners

CTS Corporation Expands Availability of Current Sensing Solutions Through Authorized Distribution Partners

CTS Corporation announced that its current sensing solutions are now available through a wider network of authorized distribution partners. This expansion aims to provide faster access, local support, and scalable supply for customers in diverse, fast-growing markets including data centers, industrial automation, medical devices, aerospace, and tel…

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

NewAmsterdam Pharma announced upcoming presentations at the European Society of Cardiology Congress highlighting data from its late-stage trials of obicetrapib, a novel oral CETP inhibitor designed to lower LDL cholesterol in patients at risk of cardiovascular disease. The company has completed enrollment in a large Phase 3 outcomes trial and partn…